



Bafilomycin response with predicted AKT
p-value: 0.06




Doxorubicin response with predicted AKT
p-value: 0.08




Neratinib response with predicted AKT

p-value: 0.04




Doxorubicin response with predicted BAD

p-value: 0.04




Neratinib response with predicted BAD

p-value: 0.08




Bafilomycin response with predicted HER2
p-value: 0.09




Neratinib response with predicted HER2

p-value: 0




Palbociclib response with predicted HER2


p-value: 0.06




Bafilomycin response with predicted IGF1R
p-value: 0.09




Doxorubicin response with predicted IGF1R
p-value: 0.03




Neratinib response with predicted IGF1R
p-value: 0.07




Doxorubicin response with predicted RAF
p-value: 0.07



Bafilomycin response with predicted EGFR
p-value: 0.06




Doxorubicin response with predicted EGFR
p-value: 0.03




Nevitaclox response with predicted EGFR

p-value: 0.06




Palbociclib response with predicted EGFR
p-value: 0.06




Erlotinib response with predicted KRASGV

p-value: 0.05




Nevitaclax response with predicted KRASGV
p-value: 0.07



Erlotinib response with predicted KRASQ_H

p-value: 0.05



Nevitaclax response with predicted KRASQH
p-value: 0.07

